F. Lamoureux, V. Trichet, C. Chipoy, F. Blanchard, F. Gouin et al., Recent advances in the management of osteosarcoma and forthcoming therapeutic strategies, Expert Rev Anticancer Ther, vol.7, issue.2, pp.169-81, 2007.

G. Rosen, M. L. Murphy, A. G. Huvos, M. Gutierrez, and R. C. Marcove, Chemotherapy, en bloc resection, and prosthetic bone replacement in the treatment of osteogenic sarcoma, Cancer, vol.37, issue.1, pp.1-11, 1976.

J. A. Lee, Osteosarcoma in Korean children and adolescents, Korean J Pediatr, vol.58, issue.4, pp.123-131, 2015.

J. P. He, Y. Hao, X. L. Wang, X. J. Yang, J. F. Shao et al., Review of the molecular pathogenesis of osteosarcoma, Asian Pac J Cancer Prev, vol.15, issue.15, pp.5967-76, 2014.

H. K. Brown, K. Schiavone, F. Gouin, M. F. Heymann, and D. Heymann, Biology of bone sarcomas and new therapeutic developments, Calcif Tissue Int, vol.102, issue.2, pp.174-95, 2018.
URL : https://hal.archives-ouvertes.fr/inserm-01653600

L. S. Goodman and M. M. Wintrobe, Nitrogen mustard therapy; use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders, J Am Med Assoc, vol.132, pp.126-158, 1946.

S. Farber, Some observations on the effect of folic acid antagonists on acute leukemia and other forms of incurable cancer, Blood, vol.4, issue.2, pp.160-167, 1949.

K. Cheung-ong, G. Giaever, and C. Nislow, DNA-damaging agents in cancer chemotherapy: serendipity and chemical biology, Chem Biol, vol.20, issue.5, pp.648-59, 2013.

H. J. Park, J. S. Bae, K. M. Kim, Y. J. Moon, S. H. Park et al., The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma, J Exp Clin Cancer Res, vol.37, issue.1, p.107, 2018.

Z. Zou, H. Chang, H. Li, and S. Wang, Induction of reactive oxygen species: an emerging approach for cancer therapy, Apoptosis, vol.22, issue.11, pp.1321-1356, 2017.

Y. Nakabeppu, S. Oka, Z. Sheng, D. Tsuchimoto, and K. Sakumi, Programmed cell death triggered by nucleotide pool damage and its prevention by MutT homolog-1 (MTH1) with oxidized purine nucleoside triphosphatase, Mutat Res, vol.703, issue.1, pp.51-59, 2010.

Y. Nakabeppu, E. Ohta, and N. Abolhassani, MTH1 as a nucleotide pool sanitizing enzyme: friend or foe?, Free Radic Biol Med, vol.107, pp.151-159, 2017.

K. Fujikawa, H. Kamiya, H. Yakushiji, Y. Nakabeppu, and H. Kasai, Human MTH1 protein hydrolyzes the oxidized ribonucleotide, 2-hydroxy-ATP, Nucleic Acids Res, vol.29, issue.2, pp.449-54, 2001.

G. Pizzino, N. Irrera, M. Cucinotta, G. Pallio, F. Mannino et al., Oxidative stress: harms and benefits for human health, Oxid Med Cell Longev, p.8416763, 2017.

G. Y. Liou and P. Storz, Reactive oxygen species in cancer, Free Radic Res, vol.44, issue.5, pp.479-96, 2010.

J. N. Moloney and T. G. Cotter, ROS signalling in the biology of cancer, Semin Cell Dev Biol, vol.80, pp.50-64, 2018.

P. Storz, Reactive oxygen species in tumor progression, Front Biosci, vol.10, pp.1881-96, 2005.

E. Coskun, P. Jaruga, A. S. Jemth, O. Loseva, L. D. Scanlan et al., Addiction to MTH1 protein results in intense expression in human breast cancer tissue as measured by liquid chromatography-isotope-dilution tandem mass spectrometry, DNA Repair, vol.33, pp.101-111, 2015.

T. Obtulowicz, M. Swoboda, E. Speina, D. Gackowski, R. Rozalski et al., Oxidative stress and 8-oxoguanine repair are enhanced in colon adenoma and carcinoma patients, Mutagenesis, vol.25, issue.5, pp.463-71, 2010.

T. Tsuzuki, A. Egashira, H. Igarashi, T. Iwakuma, Y. Nakatsuru et al., Spontaneous tumorigenesis in mice defective in the MTH1 gene encoding 8-oxo-dGTPase, Proc Natl Acad Sci, vol.98, issue.20, pp.11456-61, 2001.

H. Gad, T. Koolmeister, A. S. Jemth, S. Eshtad, S. A. Jacques et al., MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool, Nature, vol.508, issue.7495, pp.215-236, 2014.

W. Berglund, U. Sanjiv, K. Gad, H. Kalderen, C. Koolmeister et al., Validation and development of MTH1 inhibitors for treatment of cancer, Ann Oncol, vol.27, issue.12, pp.2275-83, 2016.

K. V. Huber, E. Salah, B. Radic, M. Gridling, J. M. Elkins et al., Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy, Nature, vol.508, issue.7495, pp.222-229, 2014.
URL : https://hal.archives-ouvertes.fr/hal-02168081

X. Qing, Z. Shao, X. Lv, F. Pu, F. Gao et al., Anticancer effect of (S)-crizotinib on osteosarcoma cells by targeting MTH1 and activating reactive oxygen species, Anticancer Drugs, vol.29, issue.4, pp.341-52, 2018.

T. Kawamura, M. Kawatani, M. Muroi, Y. Kondoh, Y. Futamura et al., Proteomic profiling of small-molecule inhibitors reveals dispensability of MTH1 for cancer cell survival, Sci Rep, vol.6, p.26521, 2016.

J. G. Kettle, H. Alwan, M. Bista, J. Breed, N. L. Davies et al., Potent and selective inhibitors of MTH1 probe its role in cancer cell survival, J Med Chem, vol.59, issue.6, pp.2346-61, 2016.

G. J. Samaranayake, M. Huynh, and P. Rai, MTH1 as a chemotherapeutic target: the elephant in the room, Cancers, vol.9, issue.5, 2017.

A. Petrocchi, E. Leo, N. J. Reyna, M. M. Hamilton, X. Shi et al., Identification of potent and selective MTH1 inhibitors, Bioorg Med Chem Lett, vol.26, issue.6, pp.1503-1510, 2016.

M. Baud'huin, F. Lamoureux, C. Jacques, R. Calleja, L. Quillard et al., Inhibition of BET proteins and epigenetic signaling as a potential treatment for osteoporosis, Bone, vol.94, pp.10-21, 2017.

P. Rai, T. T. Onder, J. J. Young, J. L. Mcfaline, B. Pang et al., Continuous elimination of oxidized nucleotides is necessary to prevent rapid onset of cellular senescence, Proc Natl Acad Sci, vol.106, issue.1, pp.169-74, 2009.

L. Struthers, R. Patel, J. Clark, and S. Thomas, Direct detection of 8-oxodeoxyguanosine and 8-oxoguanine by avidin and its analogues, Anal Biochem, vol.255, issue.1, pp.20-31, 1998.

M. Molina, D. Jafari, R. Ignatushchenko, M. Seki, T. Larsson et al., Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay, Science, vol.341, issue.6141, pp.84-91, 2013.

S. Burma, B. P. Chen, M. Murphy, A. Kurimasa, and D. J. Chen, ATM phosphorylates histone H2AX in response to DNA double-strand breaks, J Biol Chem, vol.276, issue.45, pp.42462-42469, 2001.

A. Georgoulis, C. E. Vorgias, G. P. Chrousos, and E. P. Rogakou, Genome instability and gam-maH2AX, Int J Mol Sci, vol.18, issue.9, 2017.

P. Rai, J. J. Young, D. G. Burton, M. G. Giribaldi, T. T. Onder et al., Enhanced elimination of oxidized guanine nucleotides inhibits oncogenic RAS-induced DNA damage and premature senescence, Oncogene, vol.30, issue.12, pp.1489-96, 2011.

T. Helleday, Cancer phenotypic lethality, exemplified by the non-essential MTH1 enzyme being required for cancer survival, Ann Oncol, vol.25, issue.7, pp.1253-1258, 2014.

L. Pudelko, P. Rouhi, K. Sanjiv, H. Gad, C. Kalderen et al., Glioblastoma and glioblastoma stem cells are dependent on functional MTH1, Oncotarget, vol.8, issue.49, pp.84671-84, 2017.

W. Zhou, L. Ma, J. Yang, H. Qiao, L. Li et al., Potent and specific MTH1 inhibitors targeting gastric cancer, Cell Death Dis, vol.10, issue.6, p.434, 2019.

H. Gad, O. Mortusewicz, S. G. Rudd, A. Stolz, N. Amaral et al., MTH1 promotes mitotic progression to avoid oxidative DNA damage in cancer cells. bio-Rxiv, p.575290, 2019.

H. Abbas, K. Alhamoudi, M. D. Evans, G. Jones, and S. S. Foster, MTH1 deficiency selectively increases non-cytotoxic oxidative DNA damage in lung cancer cells: more bad news than good?, BMC Cancer, vol.18, issue.1, p.423, 2018.

L. M. Van-der-waals, J. Laoukili, J. Jongen, D. A. Raats, I. Borel-rinkes et al., Differential anti-tumour effects of MTH1 inhibitors in patient-derived 3D colorectal cancer cultures, Sci Rep, vol.9, issue.1, p.819, 2019.

M. Pompsch, J. Vogel, F. Classen, P. Kranz, G. Iliakis et al., The presumed MTH1-inhibitor TH588 sensitizes colorectal carcinoma cells to ionizing radiation in hypoxia, BMC Cancer, vol.18, issue.1, p.1190, 2018.

C. Redon, D. Pilch, E. Rogakou, O. Sedelnikova, K. Newrock et al., Histone H2A variants H2AX and H2AZ, Curr Opin Genet Dev, vol.12, issue.2, pp.162-171, 2002.

A. Chalopin, M. Tellez-gabriel, H. K. Brown, F. Vallette, M. F. Heymann et al., Isolation of circulating tumor cells in a preclinical model of osteosarcoma: effect of chemotherapy, J Bone Oncol, vol.12, pp.83-90, 2018.
URL : https://hal.archives-ouvertes.fr/inserm-01851614

M. Li, Y. Lu, Z. Long, M. Li, J. Kong et al., Prognostic and clinicopathological significance of circulating tumor cells in osteosarcoma, J Bone Oncol, vol.16, p.100236, 2019.

K. D. Arczewska, A. Stachurska, M. Wojewodzka, K. Karpinska, M. Kruszewski et al., hMTH1 is required for maintaining migration and invasion potential of human thyroid cancer cells, DNA Repair, vol.69, pp.53-62, 2018.